Is Your Pain Medication Making Your Pain Worse?

If you have been taking opioid pain medication for a long time, you may have lived through something
that makes no sense on paper. The dose went up, and the pain got worse. Not the same — worse.

Most people assume one of two things when that happens: either the underlying disease is progressing,
or they are becoming a complainer. There is a third explanation, and it has a name in the medical
literature: opioid-induced hyperalgesia. This article is about how to recognise it, and
about the three other problems that look exactly like it and must be ruled out first.

Hyperalgesia is not the same as tolerance

Hyperalgesia means increased sensitivity to pain. Opioid-induced hyperalgesia means the medication
taken to reduce pain has begun to amplify it. The nervous system has become a louder amplifier, and the
drug is what turned up the gain.

That is a different problem from tolerance, and the difference decides what happens next. With
tolerance, the drug still works — you simply need more of it for the same relief. With hyperalgesia, the
pain system has been recalibrated. More drug does not fix it; more drug feeds it.

The practical way to tell them apart is what a dose increase actually buys. With tolerance it helps,
at least for a while. With hyperalgesia it buys a brief improvement and then a worse baseline. The pain
often spreads beyond the original injury, becomes more diffuse and burning, and ordinary sensations that
should not hurt begin to hurt — bedsheets, a light touch, a shower.

If that describes you, you are not imagining it and you are not failing at being a patient.

Why continuous exposure does this

The mu-opioid receptor is not a simple on-off switch. It is a regulated protein designed to be
stimulated intermittently. When an opioid binds, the receptor’s C-terminal tail is phosphorylated, which
recruits beta-arrestin proteins that pull the receptor into the cell and uncouple it from its signalling
partner. That is desensitisation, and it is a thermostat rather than a malfunction — the receptor is
meant to recover between doses.

Remove the recovery window by keeping an agonist present around the clock, and the thermostat becomes
a permanent state of downregulation. Birdsong and colleagues described this regulatory mechanism at the
receptor in Molecular Pharmacology in 2015. That is cellular work — it explains a mechanism, not
a clinical outcome — and the fuller mechanistic account is in our companion article on why long-acting opioids can make pain worse.

Four problems that look identical from the outside

This is why hyperalgesia gets missed. There are at least four reasons a long-term opioid patient
reports worsening pain, and they all produce the same sentence: it is not working any more, and I
need more.

1. Tolerance. The drug is still effective, the receptor system has adapted, and a dose
   increase genuinely helps.
2. Disease progression. Something structural actually got worse — a disc extruded, a
   joint collapsed, a nerve became entrapped. The pain report is accurate and the medication was never the
   issue.
3. Between-dose withdrawal. With short-acting agents, each dose wearing off produces a
   mild withdrawal state, which is itself painful and heightens pain sensitivity. It mimics hyperalgesia
   closely and is treated differently — usually by adjusting interval and timing rather than total dose.
4. Opioid-induced hyperalgesia.

Four different problems, one presenting complaint. Treat all four by escalating and you are wrong
three times out of four.

How it is actually distinguished

Partly by pattern: hyperalgesia tends to spread beyond the dermatome or the joint that was injured,
tends to bring allodynia, and tends not to respond durably to increases.

Partly by ruling things out: we re-image where indicated and use electrodiagnostic testing — EMG and
nerve conduction studies — to see whether a structural or neurological explanation has been missed.
Hyperalgesia is not a diagnosis of convenience.

And partly by a careful, monitored trial of reduction. If a slow, supported dose reduction is followed
by pain that improves rather than worsens, that is highly informative — and in many cases it is the only
way to know. That requires trust, because it asks a frightened patient to go down before going up, which
is why it is done gradually and never as an ultimatum.

What replaces the dose

If hyperalgesia is suspected, the counterintuitive move is the right one: reduce carefully rather than
escalate. Tapering here is not the withdrawal of support — it is the measurement of the body’s improved
self-regulation as the pharmacological noise is removed, calculated from clinical stability, progress in
movement and metabolic markers rather than an arbitrary schedule.

That distinction matters because the opposite failure is also real: research has associated dose
tapering with increased long-term risk of overdose and mental health crisis, which is precisely why it
must be gradual, monitored, and accompanied by something that replaces the medication. In our practice
that means interventional treatment aimed at the actual pain generator, a minimum of twelve physical
therapy sessions a year, psychological support, sleep and circadian repair, and metabolic work — because
chronic pain is frequently an extension of systemic metabolic inflammation rather than a purely
neurological event.

Related reading: Opioid bankruptcy: why opioids stop working explains why your own endorphin system is the other half of this picture, and
Pill counts vs. pharmacology covers what we tell pharmacists and referring physicians. For the full context of our approach, see
interventional pain management in St. Louis and our pain treatment FAQs.

Frequently asked questions

What is opioid-induced hyperalgesia?

It is a state in which pain sensitivity increases because of the opioid rather than despite it. Continuous stimulation of the mu-opioid receptor drives desensitisation, and the nervous system compensates by amplifying pain signalling. The practical signature is a dose increase that buys a brief improvement and then a worse baseline. Individual results vary.

How is it different from tolerance?

With tolerance the drug still works and a higher dose genuinely helps. With hyperalgesia the pain system itself has been recalibrated, so a higher dose feeds the problem. Pain also tends to spread beyond the original injury, change character to something more diffuse and burning, and bring allodynia — where a light touch or a bedsheet hurts.

Does this mean opioids are always harmful?

No. Opioids have a legitimate role in acute, post-surgical and cancer pain, and some patients with severe complex pain need them long term. The concern is continuous, escalating exposure with no plan to reduce it. Do not start, stop, or change any prescribed medication on your own — that decision belongs with your physician, and abrupt discontinuation carries real risk.

How do you tell hyperalgesia apart from the disease simply getting worse?

By pattern, by exclusion and by a monitored trial. Hyperalgesia tends to spread beyond the original anatomical territory and not respond durably to increases. We re-image where indicated and use electrodiagnostic testing to look for a structural or neurological explanation that has been missed. Where it remains unclear, a slow, supported dose reduction is often the only way to know.

Is the evidence for hyperalgesia settled?

Not entirely, and we say so. Systematic reviews support that opioid exposure can increase pain sensitivity in people, but a randomised placebo-controlled trial of sustained-release morphine in chronic low-back pain found clear analgesic tolerance without demonstrable hyperalgesia. The honest position is that it happens in some patients on long-term therapy, is under-recognised, and should be actively looked for rather than assumed either way.

Where are you located and how do I make an appointment?

Padda Institute Center for Interventional Pain Management, 4477 Woodson Road, Suite 100, St. Louis, MO 63134. Book at painmd.tv/appointment/, call (314) 481-5000 or text (314) 886-5902.

Key takeaways

• Opioid-induced hyperalgesia is increased pain sensitivity caused by the opioid, not merely despite it.
• It is distinct from tolerance: with tolerance a higher dose helps, with hyperalgesia it feeds the problem.
• Three other problems look identical — tolerance, disease progression, and between-dose withdrawal — and escalating treats all four the same wrong way.
• The evidence supports the phenomenon but is not unanimous; one randomised trial found tolerance without demonstrable hyperalgesia.
• If your dose has been climbing along with your pain, that pattern is information worth raising with your physician — never adjust medication on your own.

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary. Do not start, stop, or change any medication without consulting your physician. Opioid withdrawal can be medically hazardous and abrupt discontinuation carries real risk.

References

1. Birdsong WT, Arttamangkul S, Bunzow JR, Williams JT. Agonist binding and desensitization of the μ-opioid receptor is modulated by phosphorylation of the C-terminal tail domain. Mol Pharmacol. 2015;88(4):816–24. PMID 25934731. Cellular work describing a receptor mechanism, not a clinical outcome.
2. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104(3):570–87. PMID 16508405.
3. Higgins C, Smith BH, Matthews K. Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. Br J Anaesth. 2019;122(6):e114–e126. PMID 30915985.
4. Mercadante S, Arcuri E, Santoni A. Opioid-induced tolerance and hyperalgesia. CNS Drugs. 2019;33(10):943–55. PMID 31578704.
5. Chu LF, D’Arcy N, Brady C, et al. Analgesic tolerance without demonstrable opioid-induced hyperalgesia: a double-blinded, randomized, placebo-controlled trial of sustained-release morphine for chronic nonradicular low-back pain. Pain. 2012;153(8):1583–92. PMID 22704854. Counter-evidence.
6. Fenton JJ, Magnan E, Tseregounis IE, Xing G, Agnoli AL, Tancredi DJ. Long-term risk of overdose or mental health crisis after opioid dose tapering. JAMA Netw Open. 2022;5(6):e2216726. PMID 35696163.
7. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR Recomm Rep. 2022;71(3):1–95. PMID 36327391.

Dr. Gurpreet Singh Padda, MD, MBA, MHP , MD, MBA, MHP